Ingancin Dogon Lokaci na Maganin Kwayoyin CAR na CD19 wajen Magance Cutar Leukemia Mai Lalacewa/Rage Ragewa
A wani gagarumin ci gaba a fannin ilimin jini, wani bincike da aka yi kwanan nan ya nuna ingancin maganin CD19 chimeric antigen receptor (CAR) na T-cell a cikin marasa lafiya da ke fama da cutar sankarar jini mai tsanani (ALL) bayan allurar ƙwayoyin jini (allo-HSCT). Binciken, wanda ke bin diddigin marasa lafiya na tsawon lokaci, ya bayar da cikakken bincike kan sakamakon, yana ba da haske mai mahimmanci game da dorewa da amincin wannan sabon magani.
Binciken ya bi diddigin marasa lafiya da aka yi wa maganin ƙwayoyin T na CD19 CAR bayan sun sake komawa DUK bayan an yi musu allurar allo-HSCT. Sakamakon yana da kyau, yana nuna cewa adadi mai yawa na marasa lafiya sun sami cikakkiyar gafara, tare da ci gaba da lura da martani tsawon shekaru. Wannan binciken ba wai kawai ya nuna yuwuwar maganin ƙwayoyin T na CAR ba, har ma yana nuna wani muhimmin ci gaba a cikin maganin cututtukan jini, musamman ga waɗanda ke da ƙarancin zaɓuɓɓukan magani.
Bugu da ƙari, binciken ya zurfafa cikin yanayin aminci na maganin, yana ba da rahoton illolin da za a iya sarrafawa, waɗanda suka yi daidai da binciken da aka yi a baya. Wannan yana ƙarfafa ƙarfin gwiwa da ake da shi game da maganin ƙwayoyin CAR T a matsayin magani mai inganci da tasiri ga duk waɗanda suka sake dawowa/ba sa son yin dashen, musamman a yanayin bayan dashen.
Kamar yadda fannin Maganin rigakafi Wannan binciken ya ci gaba da bunkasa, kuma yana aiki a matsayin wata alama ta bege ga marasa lafiya da masu samar da kiwon lafiya, yana mai alƙawarin makomar da ƙarin marasa lafiya za su iya samun gafara na dogon lokaci. Binciken ba wai kawai yana ba da gudummawa ga ƙaruwar shaidun da ke tallafawa maganin ƙwayoyin CAR T ba, har ma yana buɗe hanyar ƙarin bincike don ingantawa da faɗaɗa amfani da shi a wuraren asibiti.
Da wannan ci gaba, ƙungiyar likitoci ta kusa ƙarasa sauya yanayin maganin cututtukan jini, wanda ke ba wa marasa lafiya da ke fama da waɗannan matsalolin bege.